https://doi.org/10.55788/c9f74b64
The NADIM II trial (NCT03838159) randomised 90 patients with resectable stage IIIA–IIIB NSCLC 2:1 to neoadjuvant nivolumab plus chemotherapy or chemotherapy alone. The primary analysis showed a benefit of the experimental treatment over chemotherapy alone with regard to pathologic complete response rates (pCR; 36.8% vs 6.9%; 95% CI 1.70–36.51; P=0.0068) [2]. At WCLC 2022, Dr Mariano Provencio (Hospital Universitario Puerta de Hierro-Majadahonda, Spain) presented the PFS and OS results of this trial after a median follow-up of 26.1 months.
The PFS data favoured the combination therapy arm over the monotherapy arm (median PFS not reached vs 18.3 months; HR 0.48; P=0.025), with corresponding PFS rates of 66.6% vs 42.3%. Similarly, patients who received nivolumab plus chemotherapy had an OS benefit over patients who only received chemotherapy (OS rates 84.7% vs 63.4%; HR 0.40; P=0.034). According to Dr Provencio, these results confirm the superiority of neoadjuvant nivolumab plus chemotherapy over chemotherapy alone in patients with resectable stage IIIA–IIIB NSCLC.
- Provencio M, et al. Progression free survival and overall survival in NADIM II study. PL03.12, WCLC 2022, Vienna, Austria, 06–09 August.
- Provencio M, et al. Abstract 8501, 2022 ASCO Annual Meeting, Chicago, IL, USA, 03–07 June.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC? Next Article
NADIM: Risk of progression identified through RNA sequencing »
« POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC? Next Article
NADIM: Risk of progression identified through RNA sequencing »
Table of Contents: WCLC 2022
Featured articles
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
WCLC 2022 Congress Round-Up
Sugemalimab offers PFS benefits for unresectable NSCLC
First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC
IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC
Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?
NADIM: Risk of progression identified through RNA sequencing
NADIM II: OS benefit of neoadjuvant nivolumab plus chemotherapy in NSCLC
POSEIDON: Novel option for harder-to-treat subgroups of patients with metastatic NSCLC?
First DLL3-targeted therapy shows promise in SCLC
KEYNOTE-604: Very durable responses on pembrolizumab plus EP in SCLC
Talazoparib plus temozolomide appears efficacious in ES-SCLC
Pembrolizumab plus lenvatinib performs well in MPM
Early detection strategies in younger patients with lung cancer are urgently needed
Intensive co-located smoking cessation programme highly effective during lung screening
Do we underestimate the effect of air pollution on lung cancer incidence?
Interventions needed to address sexual health in lung cancer
Related Articles


October 7, 2020
Bristol Myers’ Opdivo succeeds in late-stage lung cancer trial
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com